Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 clinical testing of Anti-Coronavirus-antibodies

Trial Profile

Phase 1/2 clinical testing of Anti-Coronavirus-antibodies

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2020

At a glance

  • Drugs Anti Coronavirus antibodies Vir Biotechnology (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Vir Biotechnology
  • Most Recent Events

    • 30 Mar 2020 New trial record
    • 25 Mar 2020 According to a Vir Biotechnology media release, clinical testing planned for this summer

Trial Overview

Purpose

Phase 1/2 clinical testing of Anti-Coronavirus-antibodies

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex not stated

Trial Details

Organisations

  • Sponsors Vir Biotechnology
  • Affiliations Vir Biotechnology

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I/II
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Anti Coronavirus antibodies Vir BiotechnologyPrimary Drug Parenteral
-

Anti-Coronavirus-antibodies

Trial Centres

Centres

Centre Name Location Trial Centre Country
Vir Biotechnology
-
-

Trial History

Event Date Event Type Comment
30 Mar 2020 New trial record New trial record Updated 30 Mar 2020
25 Mar 2020 Other trial event According to a Vir Biotechnology media release, clinical testing planned for this summer Updated 01 Apr 2020

References

  1. Vir Biotechnology. Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19. Media-Rel 2020;.

    Media Release
Back to top